Literature DB >> 32499156

Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation.

Aydin Eresen1, Jia Yang1, Junjie Shangguan1, Al B Benson2, Vahid Yaghmai3, Zhuoli Zhang4.   

Abstract

RATIONALE AND
OBJECTIVES: To develop classification and regression models interpreting tumor characteristics obtained from structural (T1w and T2w) magnetic resonance imaging (MRI) data for early detection of dendritic cell (DC) vaccine treatment effects and prediction of long-term outcomes for LSL-KrasG12D; LSL-Trp53R172H; Pdx-1-Cre (KPC) transgenic mice model of pancreatic ductal adenocarcinoma.
MATERIALS AND METHODS: Eight mice were treated with DC vaccine for 3 weeks while eight KPC mice were used as untreated control subjects. The reproducibility of the computed 264 features was evaluated using the intraclass correlation coefficient. Key variables were determined using a three-step feature selection approach. Support vector machines classifiers were generated to differentiate treatment-related changes on tumor tissue following first- and third weeks of the DC vaccine therapy. The multivariable regression models were generated to predict overall survival (OS) and histological tumor markers of KPC mice using quantitative features.
RESULTS: The quantitative features computed from T1w MRI data have better reproducibility than T2w MRI features. The KPC mice in treatment and control groups were differentiated with a longitudinally increasing accuracy (first- and third weeks: 87.5% and 93.75%). The linear regression model generated with five features of T1w MRI data predicted OS with a root-mean-squared error (RMSE) <6 days. The proposed multivariate regression models predicted histological tumor markers with relative error <2.5% for fibrosis percentage (RMSE: 0.414), CK19+ area (RMSE: 0.027), and Ki67+ cells (RMSE: 0.190).
CONCLUSION: Our results demonstrated that proposed models generated with quantitative MRI features can be used to detect early treatment-related changes in tumor tissue and predict OS of KPC mice following DC vaccination.
Copyright © 2020 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dendritic cell vaccine treatment; machine learning; magnetic resonance imaging; pancreatic ductal adenocarcinoma; structural MRI radiomics analysis

Mesh:

Year:  2020        PMID: 32499156      PMCID: PMC7704817          DOI: 10.1016/j.acra.2020.04.026

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   5.482


  23 in total

1.  Radiomics signature for the preoperative assessment of stage in advanced colon cancer.

Authors:  Yu Li; Aydin Eresen; Yun Lu; Jia Yang; Junjie Shangguan; Yury Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

Review 2.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

3.  Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model.

Authors:  Anna Shangguan; Na Shang; Matteo Figini; Liang Pan; Jia Yang; Quanhong Ma; Su Hu; Aydin Eresen; Chong Sun; Bin Wang; Yuri Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Cytotherapy       Date:  2020-01       Impact factor: 5.414

Review 4.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Authors:  Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

5.  Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

Authors:  L Zahradova; K Mollova; D Ocadlikova; L Kovarova; Z Adam; M Krejci; L Pour; A Krivanova; V Sandecka; R Hajek
Journal:  Neoplasma       Date:  2012       Impact factor: 2.575

6.  Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

Authors:  Erik H J G Aarntzen; I Jolanda M De Vries; W Joost Lesterhuis; Danita Schuurhuis; Joannes F M Jacobs; Kalijn Bol; Gerty Schreibelt; Roel Mus; Johannes H W De Wilt; John B A G Haanen; Dirk Schadendorf; Alexandra Croockewit; Willeke A M Blokx; Michelle M Van Rossum; William W Kwok; Gosse J Adema; Cornelis J A Punt; Carl G Figdor
Journal:  Cancer Res       Date:  2012-10-18       Impact factor: 12.701

7.  Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.

Authors:  Chie Oshita; Masako Takikawa; Akiko Kume; Haruo Miyata; Tadashi Ashizawa; Akira Iizuka; Yoshio Kiyohara; Shusuke Yoshikawa; Ryuji Tanosaki; Naoya Yamazaki; Akifumi Yamamoto; Kazutoh Takesako; Ken Yamaguchi; Yasuto Akiyama
Journal:  Oncol Rep       Date:  2012-08-07       Impact factor: 3.906

8.  A Fully-Automatic Multiparametric Radiomics Model: Towards Reproducible and Prognostic Imaging Signature for Prediction of Overall Survival in Glioblastoma Multiforme.

Authors:  Qihua Li; Hongmin Bai; Yinsheng Chen; Qiuchang Sun; Lei Liu; Sijie Zhou; Guoliang Wang; Chaofeng Liang; Zhi-Cheng Li
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

9.  Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Farzad Khalvati; Yucheng Zhang; Sameer Baig; Edrise M Lobo-Mueller; Paul Karanicolas; Steven Gallinger; Masoom A Haider
Journal:  Sci Rep       Date:  2019-04-01       Impact factor: 4.379

10.  MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma.

Authors:  Aydin Eresen; Jia Yang; Junjie Shangguan; Yu Li; Su Hu; Chong Sun; Yury Velichko; Vahid Yaghmai; Al B Benson; Zhuoli Zhang
Journal:  J Transl Med       Date:  2020-02-10       Impact factor: 5.531

View more
  4 in total

Review 1.  Challenges in ensuring the generalizability of image quantitation methods for MRI.

Authors:  Kathryn E Keenan; Jana G Delfino; Kalina V Jordanova; Megan E Poorman; Prathyush Chirra; Akshay S Chaudhari; Bettina Baessler; Jessica Winfield; Satish E Viswanath; Nandita M deSouza
Journal:  Med Phys       Date:  2021-09-29       Impact factor: 4.506

2.  Early assessment of irreversible electroporation ablation outcomes by analyzing MRI texture: preclinical study in an animal model of liver tumor.

Authors:  Aydin Eresen; Kang Zhou; Chong Sun; Junjie Shangguan; Bin Wang; Liang Pan; Su Hu; Yongsheng Pang; Zigeng Zhang; Robert Minh Nhat Tran; Ajeet Pal Bhatia; Farouk Nouizi; Nadine Abi-Jaoudeh; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 3.  Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?

Authors:  Roger Sun; Théophraste Henry; Adrien Laville; Alexandre Carré; Anthony Hamaoui; Sophie Bockel; Ines Chaffai; Antonin Levy; Cyrus Chargari; Charlotte Robert; Eric Deutsch
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 4.  Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.

Authors:  Laurent Dercle; Jeremy McGale; Shawn Sun; Aurelien Marabelle; Randy Yeh; Eric Deutsch; Fatima-Zohra Mokrane; Michael Farwell; Samy Ammari; Heiko Schoder; Binsheng Zhao; Lawrence H Schwartz
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.